Wahler, Steffen; Müller, Alfred; Fuchs, Sabine; … - In: Health economics review 12 (2022) 1, pp. 1-14
evaluates the cost-effectiveness of both treatment alternatives (dabrafenib/trametinib and nivolumab) against observation as a … life years of 2.28 QALY at an incremental lifetime cost of 86.1 T€. The incremental cost effectiveness ratio of dabrafenib … turned out to be cost effective within internationally accepted Incremental Cost Effectiveness Ratio (ICER) thresholds with …